JPM cautious view on Sartorius Q1 results drags shares

** Shares in Sartorius SRT and its French subsidiary Sartorius Stedim Biotech DIM slide around 4% after JP Morgan takes cautious stance on profits and sales ahead of Q1 results

** For Q1 2025, the broker expects underlying EBITDA to come 3% below consensus for Sartorius and 4% below consensus for Sartorius Stedim Biotech

** For 2025, JPM expects sales of 3.52 bln euros for Sartorius and 2.92 bln euros for Stedim (4 and 5% below consensus, respectively)

** The broker anticipates the group to release sales growth in a mid-single digit range and margin expansion to around 29%, which could result in 6% cuts to SRT3/DIM EBITDA consensus

** Shares in Sartorius are among worst performers on the Europe stock 600 index SXXP

** Sartorius will report Q1 results on April 16